The binary event is the CHAPTER-3 topline data expected within the next ~6 weeks. A positive readout would validate the XR prophylaxis program and significantly de-risk the pipeline, while a negative or mixed result would be a major setback. Traders should position for high volatility around the data release, with the PDUFA date in April 2027 providing a longer-term catalyst.
Drug in focus
PHVS drug pipeline →deucrictibant
◆ Mixed Named in this 6-K- Impact
- Phase
- Filed/PDUFA (IR capsule); Phase 3 (XR tablet)
- Time to market
- IR capsule could be approved by April 23, 2027 PDUFA date. XR tablet for prophylaxis would follow later, likely 2028+ if CHAPTER-3 is positive.
- Next catalyst
- None dated
What to watchTwo binary catalysts in the next ~9 months: CHAPTER-3 topline (Q3 2026) and the PDUFA decision on the IR capsule (April 23, 2027). The bigger swing factor near-term is CHAPTER-3, a positive readout would validate the larger prophylactic market opportunity, while a miss would severely dent the thesis given that sebetralstat (KalVista) already beat deucrictibant to market as the first oral on-demand HAE therapy.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 12 $36.46entry
- T+1 · 3mo ago −6.64%α −7.34% · $34.04
- T+5 · 3mo ago −0.52%α −0.08% · $36.27
- T+20 · 2mo ago +2.88%α +4.78% · $37.51
- T+60 · 12d ago −5.84%α −0.97% · $34.33
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pharvaris reported Q2 2026 financial results with no revenue, a net loss of €47.8M (€0.70/share), and cash of €318M. The key catalyst is the expected topline data from the CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis in 3Q2026, alongside the ongoing FDA review of the deucrictibant IR NDA with a PDUFA date of April 23, 2027. The May 2026 $132M offering extends the cash runway into 2028, funding pre-commercial activities and lifecycle management, but the pre-revenue stage and increasing operating losses keep the stock binary on pipeline execution.
Key Facts
- No revenue generated for Q2 2026 or Q2 2025.
- Net loss of €47.8M for Q2 2026 vs €45.5M for Q2 2025.
- Cash and cash equivalents of €318M as of June 30, 2026, up from €292M at Dec 31, 2025.
- Topline data from CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis expected in 3Q2026.
- Deucrictibant IR NDA under FDA review with PDUFA date of April 23, 2027; MAA validated by EMA in July 2026.
- Closed a $132.3M underwritten offering in May 2026, extending cash runway into 2028.
- R&D expenses increased 18% YoY to €35.0M; G&A expenses increased 47% YoY to €15.8M.
- Enrollment ongoing in CREAATE, a pivotal Phase 3 study for AAE-C1INH.
Financial Impact
Net loss of €47.8M in Q2 2026, with cash burn of €86.6M in operating activities for H1 2026. Cash runway extended into 2028 via $132.3M May 2026 offering.
Risk Factors
- CHAPTER-3 Phase 3 data may fail to meet primary or key secondary endpoints.
- FDA may not approve deucrictibant IR NDA by the PDUFA date or at all.
- Increasing operating losses and cash burn rate may require additional dilutive financing before reaching profitability.
- Competition from existing HAE therapies (e.g., Takhzyro, Orladeyo) could limit commercial uptake if approved.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-345702 |
| Document: phvs-ex99_2.htm | 0001193125-26-345702 |
| Document: phvs-20260630.htm | 0001193125-26-345702 |
| Document: phvs-ex99_1.htm | 0001193125-26-345702 |
| Document: 0001193125-26-345702-index-headers.html | 0001193125-26-345702 |
| Document: 0001193125-26-345702-index.html | 0001193125-26-345702 |
| Document: 0001193125-26-345702.txt | 0001193125-26-345702 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers